PRESENTATION

Q1 2024 — Results presentation

Q1 2024PDF · 20 pages1.7 MB


-- 1 of 20 --

st
April 16, 2024

-- 2 of 20 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including
technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to
successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply
chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by
government agencies; the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc; and Kenvue’s ability to succeed as a standalone publicly traded company. A
further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023,
including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form
10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at 	www.sec.gov, 	www.jnj.com 	or on request from Johnson & Johnson. Any
forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a
result of new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 20 --

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and
commercialize for a broad range of indications
Immunology
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.	Neuroscience
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and
Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS)
Infectious Diseases
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Cardiovascular/
Metabolism/Other
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab
A/S relates to several bispecific antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Oncology
UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan	Pulmonary Hypertension
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® 	is licensed-in from Bavarian Nordic A/S. The program has benefited from funding
and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-
clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176),
EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the
European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health
and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola
was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the
Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA
invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract
Number HHSN272200800056C.
Global Public Health
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 20 --

John Reed
Executive Vice President,
Innovative Medicine, R&D
Enterprise highlights
Sales performance and earnings review
Capital allocation and guidance
Q&A
Agenda
1
2
3
4
5
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
Medtech

-- 5 of 20 --

Jessica Moore
Vice President,
Investor Relations

-- 6 of 20 --

% Change
Q1 2023	Q1 2024	Regional sales results1 	Operational2
ex COVID-19 Vaccine
Operational2
Reported
7.8%	7.8%	7.8%	$10.8	$11.6	U.S.
6.0	(7.7)	(7.6)	5.6	5.2	Europe
21.3	21.3	11.0	1.1	1.2
Western Hemisphere
(ex U.S.)
5.0	5.0	(1.1)	3.4	3.4	Asia-Pacific, Africa
7.4	(0.3)	(3.4)	10.1	9.8	International
7.6%	3.9%	2.3%	$20.9	$21.4	Worldwide (WW)
Dollars in billions
1 	Results have been recast to reflect the continuing operations of Johnson & Johnson
2 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
1st Quarter 2024 sales
7

-- 7 of 20 --

$21.4 $20.9
$6.6 $6.3
12.4%; 	12.8%2
$2.71 $2.41
Dollars in billions, except EPS
Reported %; 	Operational %2
Sales
Adjusted earnings3 	Adjusted EPS3
2.3%; 	3.9%2, 7.6%2,4
GAAP earnings / (loss)
$5.4
($0.5)
3.8%
$2.20
($0.19)
Q1 2024 	Q1 2023
* Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive
1 	Results have been recast to reflect the continuing operations of Johnson & Johnson
2 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
4 	Excluding COVID-19 Vaccine
1st Quarter 2024 financial highlights1
GAAP earnings / (loss) per share
(diluted / basic*)
8
Q1 2024 	Q1 2023 	Q1 2024 	Q1 2023
Q1 2024 	Q1 2023 	Q1 2024 	Q1 2023

-- 8 of 20 --

Immunology
$4,247
Infectious Diseases
$821
Neuroscience
$1,803
Oncology
$4,814
CVM/Other
$829
PH
$1,049
■ 	Reported growth 	■ 	Operational growth1
$13,562
1.1%, 	8.3%3
WW sales $MM
Key drivers of operational performance1
• 	TREMFYA increase due to market growth and share gains
• 	SIMPONI/SIMPONI ARIA increase driven by OUS growth
• 	STELARA driven by market growth and share gains in IBD, partially offset by
unfavorable patient mix
• 	REMICADE decline due to biosimilar competition
Immunology
• 	COVID-19 Vaccine revenue decline	Infectious Diseases
• 	SPRAVATO growth driven by increased physician and patient demand
• 	Growth partially offset by declines in RISPERDAL CONSTA
Neuroscience
• 	DARZALEX increase driven by continued strong share gains in all regions
• 	ERLEADA increase driven by continued share gains and market growth
• 	CARVYKTI increase driven by continued share gains, capacity expansion, and
manufacturing efficiencies
• 	TECVAYLI driven by ongoing launch
• 	Growth in Other Oncology driven by launch of TALVEY and RYBREVANT
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA decline due to
global competitive pressure
Oncology
• 	XARELTO decline due to unfavorable patient mix and share loss
Cardiovascular /
Metabolism / Other
(CVM/Other)
• 	UPTRAVI and OPSUMIT growth driven by favorable patient mix, market growth, and
share gains
Pulmonary
Hypertension (PH)
Adjusted operational sales2,3: WW: 8.3%, U.S. 8.4%, Int’l 8.3%
Innovative Medicine highlights – 1st quarter 2024
WW 1.1%, U.S. 8.4%, Int’l (6.9)%	Reported:
WW 8.3%, U.S. 8.4%, Int’l 8.3%	Operational1,3:
(10.6)%, 	(10.5)%
20.2%, 	22.4%
17.1%, 	18.8%
(48.3)%, 	(48.3)%4 3.3%, 	4.6%
Strong adjusted operational growth1 of 8.3%3 driven by Oncology, PH, and Immunology
0.0%, 	2.2%
9
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Excluding COVID-19 Vaccine
4 	Including COVID-19 Vaccine
Note: Values may be rounded

-- 9 of 20 --

Key drivers of operational performance1
• 	Electrophysiology: Double-digit increase driven by global procedure growth, new products (QDOT,
OCTARAY), commercial execution, and Asia Pacific distributor inventory dynamics, partially offset by volume-based
procurement (VBP) in China and fewer selling days
• 	Abiomed: Strength from all major commercialized regions driven by continued strong adoption of Impella 5.5 and
Impella RP
Cardiovascular3
• 	Hips: 	Reflects global procedure growth, continued portfolio strength (primarily in the Anterior approach), and a one-
time revenue recognition timing change related to certain products in the U.S., partially offset by Russia sanctions
and one less selling day
• 	Trauma: 	Growth driven by a one-time revenue recognition timing change related to certain products in the U.S., and
continued adoption of recently launched products (Advanced Nailing Systems and Cannulated Compression
Headless Screws), partially offset by U.S. competitive challenges, fewer selling days, weather-related softness in
core trauma, and VBP
• 	Knees: 	Growth driven by procedures, continued strength of the ATTUNE portfolio (Cementless & Medial Stabilized),
pull through related to the VELYS Robotic assisted solution, a one-time revenue recognition timing change related to
certain products in the U.S., and OUS tender timing, partially offset by one less selling day
• 	Spine, Sports & Other: 	Reflects growth in Digital Solutions, Craniomaxillofacial, Shoulders, and a one-time revenue
recognition timing change related to certain products in the U.S., partially offset by spine competitive pressures and
one less selling day
• 	Spine: 	~ +1% WW, ~ +5% U.S., ~ -4% OUS
Orthopaedics
• 	Advanced:
• 	Biosurgery: 	~ +9% Increase driven by global procedures, strength of the portfolio (SURGIFLO, SURGICEL
Powder, Evarrest, and VISTASEAL), and commercial execution
• 	Endocutters: 	~ -4% Primarily due to competitive pressures in the U.S., Bariatric procedure softness, China VBP
and OUS inventory stocking dynamics and tender timing, partially offset by success of recently launched
products (ECHELON 3000)
• 	Energy: 	~ -7% Driven by competitive pressures, VBP, and Harmonic market decline in the U.S., partially offset by
uptake of new products OUS
• 	General: 	Growth primarily due to procedures coupled with technology penetration and upgrades within our
differentiated Wound Closure portfolio (Barbed & PLUS Sutures), partially offset by fewer selling days
Surgery
• 	Contact Lenses/Other: 	Driven by U.S. stocking dynamics and economic pressures in Asia Pacific, partially offset by
continued strong performance of the ACUVUE OASYS 1-Day family (including recent launch of OASYS MAX 1-day)
and price actions
• 	Surgical: 	Reflects continued strength of recent innovation (TECNIS EYHANCE & TECNIS EYHANCE Toric) and
commercial execution, partially offset by inventory revaluation in China in preparation for VBP implementation and
refractive softness in the U.S.
Vision
Adjusted operational sales2: WW 6.5%, U.S. 6.8%, Int’l 6.2%
Orthopaedics
$2,340
Surgery
$2,416
Vision
$1,258
Cardiovascular3
$1,806
■ 	Reported growth 	■ 	Operational growth1
$7,821
4.5%, 	6.3%
WW Sales $MM
Solid operational growth1 due to procedures, strong commercial execution, and innovation
WW 4.5%, U.S. 6.6%, Int’l 2.4%	Reported:
WW 6.3%, U.S. 6.6%, Int’l 6.1%	Operational1:
20.2%, 	22.5%
(3.3)%, 	(1.4)%
4.3%, 	4.8%
(0.7)%, 	1.9%
MedTech highlights – 1st quarter 2024
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Previously referred to as Interventional Solutions
Note: Values may be rounded 	10

-- 10 of 20 --

%
Increase
(Decrease)
2023	2024
% to Sales	Amount	% to Sales	Amount
2.3	100.0	$20,894	100.0	$21,383	Sales to customers
(2.6)	32.0	6,687	30.4	6,511	Cost of products sold
4.7	68.0	14,207	69.6	14,872	Gross Profit
7.2	23.5	4,906	24.6	5,257	Selling, marketing and administrative expenses
2.5	16.6	3,455	16.6	3,542	Research and development expense
0.2	49	-	-	In-process research and development impairments
0.1	14	(1.0)	(209)	Interest (income) expense, net
33.2	6,940	(1.5)	(322)	Other (income) expense, net
0.6	130	0.8	164	Restructuring
(6.2)	(1,287)	30.1	6,440	Earnings / (loss) before provision for taxes on income
(3.9)	(796)	5.1	1,086	Provision for / (Benefit from) taxes on income
(2.3)	($491)	25.0	$5,354	Net Earnings / (loss) from Continuing Operations
423	-	Net Earnings from Discontinued Operations, net of tax
($68)	$5,354	Net Earnings / (loss)
-
($0.19)	$2.20	Net earnings / (loss) per share (Diluted/Basic) from Continuing Operations
$0.16	-	Net earnings per share (Diluted) from Discontinued Operations
2,605.5*	2,430.1	Average shares outstanding (Diluted/Basic)
61.8%	16.9%	Effective tax rate from Continuing Operations
.
Adjusted earnings from Continuing Operations before provision for taxes and net earnings2
4.5	36.1	$7,536	36.8	$7,877	Earnings before provision for taxes on income from Continuing Operations
3.8	30.3	$6,340	30.8	$6,580	Net earnings from Continuing Operations
12.4	$2.41	$2.71	Net earnings per share (Diluted) from Continuing Operations
2,634.3	2,430.1	Average shares outstanding (Diluted)
15.9%	16.5%	Effective tax rate from continuing operations
* Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive
1 	Results have been recast to reflect the continuing operations of Johnson & Johnson
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
1st Quarter 2024
(Unaudited; Dollar and shares in millions except per share figures)
Condensed consolidated statement of earnings1
11

-- 11 of 20 --

Innovative Medicine
MedTech
Expenses not allocated to segments
FY 2023	Q1 2023	Q1 2024
42.0%	42.9%	42.9%
Innovative
Medicine
23.7%	26.5%	26.4%	MedTech
35.0%	36.1%	36.8%	Total
% to sales
Adjusted income before tax by segment1,2
1 	Results have been recast to reflect the continuing operations of Johnson & Johnson
2 	Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Estimated as of 4/16/2024
Note: Values may be rounded
1st Quarter 2024
$2.1 	$2.0
$5.8 	$5.8
2024 	2023
$7.5B	$7.9B
($0.2)
3
12
20243

-- 12 of 20 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 13 of 20 --

Innovative Medicine
• 	Regulatory:
– 	CARVYKTI is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received At Least One Prior Line of Therapy2
– 	Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
– 	U.S. FDA Approves OPSYNVI (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
– 	U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
– 	Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
– 	Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
– 	RYBREVANT (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
– 	Janssen Receives Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
– 	TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
– 	Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
– 	Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) based regimen for the treatment of patients with
transplant-eligible, newly diagnosed multiple myeloma
• 	Data release:
– 	Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting2
– 	RYBREVANT (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
– 	New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
– 	Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
– 	Johnson & Johnson reports positive topline results for Nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD)
– 	Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
MedTech
• 	Regulatory:
– 	Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation
• 	Product launch:
– 	Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform
Enterprise
– 	Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.242
– 	Johnson & Johnson to Acquire Shockwave Medical2
– 	Johnson & Johnson Completes Acquisition of Ambrx
Notable announcements in 1st quarter 20241
1 	These developments and all other news releases are available on the company’s website at 	News Releases 	as well as 	Innovative Medicine News Center, 	MedTech News & Events, 	www.factsabouttalc.com, and 	www.LLTManagementInformation.com
2 	Subsequent to the quarter 14

-- 14 of 20 --

Capital allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Q1 2024	Dollars in billions
$26
Cash and marketable
securities
($34)	Debt
($7)	Net debt
~$3.	Free cash flow1,2
Q1 2024:
$3.5B 	invested in R&D
$2.9B 	in dividends paid
to shareholders
Note: Values may be rounded
1 	Non-GAAP measure; defined as cash flow from operating activities less additions to property, plant and equipment
2 	Estimated as of April 16, 2024. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
Note: Values may be rounded
Capital allocation strategy
15

-- 15 of 20 --

Comments
January
2024
April
2024
Tightening range;
Increasing midpoint to 5.8%
5.0% - 6.0%	5.5% - 6.0%	Adjusted operational sales2,3,7
Tightening range;
Increasing midpoint to 5.8%
$88.2B - $89.0B
5.0% - 6.0%
$88.7B - $89.1B
5.5% - 6.0%
Operational sales3,7
Midpoint of $88.2B or 5.0%
Incremental FX ($0.3B) or (0.3%)
$87.8B - $88.6B
4.5% - 5.5%
$88.0B - $88.4B
4.7% - 5.2%
Estimated reported sales 	4,7
Maintain	Improvement of ~50 bps	Improvement of ~50 bps
Adjusted pre-tax
operating margin5,6
Maintain	$1.2 - $1.4 billion	$1.2 - $1.4 billion	Net other income5
Increase based on Q1 actuals	($450) – ($550) million	($550) – ($650) million	Net interest expense / (income)
Maintain	16.0% - 17.0%	16.0% - 17.0%	Effective tax rate5
Tightening of range;
Increasing midpoint by $0.03
$10.55 - $10.75
6.4% - 8.4%
$10.60 - $10.75
6.9% - 8.4%
Adjusted EPS (operational)3,5
Tightening of range;
Maintaining midpoint of $10.65
Incremental FX of ($0.03)
$10.55 - $10.75
6.4% - 8.4%
$10.57 - $10.72
6.6% - 8.1%
Adjusted EPS (reported)4,5
2024 P&L guidance1
Tightening the range and increasing the midpoint of operational sales and adjusted operational EPS guidance
(Guidance excludes impact from the recently announced acquisition of Shockwave Medical)
1 	Results have been recast to reflect the continuing operations of Johnson & Johnson 	5 	Non-GAAP measure; excludes intangible amortization expense and special items
2 	Non-GAAP measure; excludes acquisitions and divestitures 	6 	Sales less: COGS, SM&A and R&D expenses
3 	Non-GAAP measure; excludes the impact of translational currency 	7 	Excludes COVID-19 Vaccine
4 	Euro Average Rate: April 2024 = $1.08; Euro Spot Rate: April 2024 = $1.08 	Note: Values may be rounded 	16

-- 16 of 20 --

Innovative
Medicine
• 	Expect slightly stronger sales growth in the first half of the year compared to the second
 	Continued uptake from recently launched products
 	Anticipated entry of Stelara biosimilars in Europe towards the middle of the year
• 	Operational sales growth expected to be relatively consistent throughout the year
 	2024 procedure volumes remain above pre-COVID levels
 	Modest impact from Russia sanctions in first half of the year
 	VBP pricing for Surgical IOLs and Sports in 2024; lapping of 2023 VBP impacts throughout
the year
Phasing Considerations
MedTech
EPS growth will benefit from 191MM share reduction in the first half of the year; partial benefit in Q3	P&L
17

-- 17 of 20 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
Medtech

-- 18 of 20 --

Slide footer goes here if required 	19

-- 19 of 20 --

= 	Achieved
POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA
Sum of Check Change 	Sum of Check Change 	Sum of Check Change	Phase III
OPSUMIT (macitentan) 	US 	OPSUMIT (macitentan) 	US 	SIMPONI (golimumab) 	TREMFYA (guselkumab)
EU 	Pediatric Pulmonary Arterial Hypertension
(TOMORROW)
Pediatric Pulmonary Arterial Hypertension
(TOMORROW)
EU 	Pediatric Ulcerative Colitis 	Crohn's Disease (GALAXI)
P 	US 	OPSYNVI (macitentan/tadalafil STCT) 	UPTRAVI (selexipag) 	STELARA (ustekinumab) 	TREMFYA (guselkumab)
EU 	Pulmonary Arterial Hypertension 	EU 	Pediatric Pulmonary Arterial Hypertension
(SALTO)
EU 	Pediatric Crohn's Disease 	Ulcerative Colitis Monotherapy (QUASAR)
P 	US 	EDURANT (rilpivirine) 	US 	nipocalimab 	US 	TREMFYA (guselkumab) 	RYBREVANT (amivantamab)
EU 	HIV pediatric 2-12 year old 	EU 	Generalized Myasthenia Gravis 	Pediatric Psoriasis 	Subcutaneous (PALOMA-3)
P 	US^ 	BALVERSA (erdafitinib) 	US 	RYBREVANT (amivantamab) 	US 	TREMFYA (guselkumab) 	ERLEADA (apalutamide)
EU 	Urothelial Cancer (THOR) 	EU 	Subcutaneous (PALOMA-3) 	EU 	Crohn's Disease (GALAXI) 	High Risk Prostate Cancer (PROTEUS)
US 	DARZALEX (daratumumab) 	P 	US 	DARZALEX (daratumumab) 	US 	TREMFYA (guselkumab) 	seltorexant
Frontline multiple myeloma transplant eligible
(PERSEUS)
P 	EU 	Frontline multiple myeloma transplant
eligible (PERSEUS)
Pediatric Juvenile Psoriatic Arthritis 	Adjunctive treatment for major depressive disorder
with insomnia symptoms
P 	US 	CARVYKTI (ciltacabtagene autoleucel) 	REKAMBYS 	P 	US 	TREMFYA (guselkumab) 	nipocalimab
EU 	Relapsed Refractory multiple myeloma w/1-3
PL (CARTITUDE-4)
EU 	HIV Adolescents 	EU 	Ulcerative Colitis Monotherapy (QUASAR) 	Generalized Myasthenia Gravis
P 	US 	RYBREVANT (amivantamab) 	US 	TREMFYA (guselkumab) 	TREMFYA (guselkumab)
EU 	Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
Ulcerative Colitis Subcutaneous Induction (ASTRO) 	Crohn's Disease Subcutaneous Induction (GRAVITI)
US 	RYBREVANT / lazertinib 	US 	TREMFYA (guselkumab) 	aticaprant
EU 	Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	EU 	Crohn's Disease Subcutaneous Induction (GRAVITI) 	Adjunctive Major Depressive Disorder
US 	RYBREVANT / lazertinib 	SPRAVATO (esketamine) monotherapy
EU 	Non Small Cell Lung Cancer (MARIPOSA) 	Treatment Resistant Depression (TRD4005)
Phase II
Combination Therapy
Psoriatic Arthritis
nipocalimab
Sjogren's Disease
TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer (SunRISe-1)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2024*
*This information is as of April 16, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval

-- 20 of 20 --